Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Launched by FONDAZIONE ITALIANA LINFOMI - ETS · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a treatment called mogamulizumab for patients with cutaneous T-cell lymphoma (CTCL), a type of skin cancer. The goal is to understand how well this medication works in real-life situations, especially for those who have already tried other treatments without success. The trial is currently looking for participants who are at least 18 years old, have been diagnosed with CTCL, and have received at least one previous treatment that didn’t work for them.

If you qualify and join the study, you will receive mogamulizumab at the approved dose, which involves getting an intravenous (IV) infusion on specific days. As a participant, you will help researchers gather important information about how this treatment works in everyday settings. It’s important to note that to take part, you need to have complete medical records and have started treatment with mogamulizumab between January 2021 and January 2023. This trial aims to provide valuable insights that could help improve care for future patients with CTCL.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria (Trautinger et al, Eur J Cancer, 2017)
• • Age ≥18 years
• • Have failed at least one previous line of systemic therapy
• • Have received mogamulizumab in real life setting after the approval and reimbursement of the drug from the National Health System in December 2020
• • Have received first dose of mogamulizumab between 01/01/2021 and 31/01/2023
• • Have received mogamulizumab at the standard approved dose (1.0 mg/kg intravenously on days 1, 8, 15 and 22 of the first cycle and on days 1 and 15 of subsequent cycles)
• • Availability of complete medical records.
• Exclusion Criteria:
• • • Patients not meeting the above-mentioned inclusion criteria